Press Releases 2025 2024 2023 2022 2021 2020 2019 all November 12, 2024 Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 7, 2024 Dyne Therapeutics to Present at Upcoming Investor Conferences October 9, 2024 Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases September 23, 2024 Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference September 3, 2024 Dyne Therapeutics Announces Key Leadership Appointments September 3, 2024 Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts August 29, 2024 Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference August 12, 2024 Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights June 24, 2024 Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease June 13, 2024 Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress May 30, 2024 Dyne Therapeutics to Present at Jefferies Global Healthcare Conference May 28, 2024 Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares May 21, 2024 Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock May 20, 2024 Dyne Therapeutics Announces Proposed Public Offering of Common Stock May 20, 2024 Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints May 19, 2024 Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET May 2, 2024 Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights March 27, 2024 Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer March 27, 2024 Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium March 25, 2024 Dyne Therapeutics Announces CEO Transition Pagination Current page 1 Page 2 Next page › Last page » Displaying 1 - 20 of 30
